{
    "clinical_study": {
        "@rank": "146525", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the safety and feasibility of gene transfer with the third generation adenovirus\n      H5.001CBCFTR in patients with cystic fibrosis."
        }, 
        "brief_title": "Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis", 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: H5.001CBCFTR, an adenovirus vector containing the cystic fibrosis\n      transmembrane conductance regulator gene, is administered endobronchially.\n\n      Cohort of 2 patients receive 1 of 6 H5.001CBCFTR concentrations.  There is no intrapatient\n      dose escalation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Cystic fibrosis diagnosed as follows: Sweat sodium or chloride\n        greater than 60 mEq/L by pilocarpine iontophoresis or cystic fibrosis genotype Clinical\n        manifestations Estimated 2-year survival greater than 50%, i.e.: FEV1 at least 30% of\n        predicted PaO2 greater than 55 mm Hg on room air PaCO2 less than 50 mm Hg on room air\n        --Prior/Concurrent Therapy-- At least 2 months since systemic glucocorticoids At least 90\n        days since participation in investigational therapeutic study --Patient Characteristics--\n        Pulmonary: No pneumothorax within 12 months No asthma or allergic bronchopulmonary\n        aspergillosis requiring glucocorticoids within 2 months No sputum pathogens unless\n        sensitive to at least 2 antibiotics No hemoptysis of more than 250 mL blood over 24 hours\n        within 1 year Other: No active adenoviral infection Ad5 (or similar type) antibody\n        seropositive No other contraindication to protocol participation, e.g.: Drug abuse\n        Alcoholism Psychiatric instability Inadequate motivation Documented azoospermia (men)\n        Bilateral tubal ligation or hysterectomy (women) Screening exams within 4 weeks prior to\n        registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "14", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004287", 
            "org_study_id": "199/11715", 
            "secondary_id": "UPHS-28051"
        }, 
        "intervention": {
            "intervention_name": "H5.001CBCFTR", 
            "intervention_type": "Genetic"
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "cystic fibrosis", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "James M. Wilson", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "10609658", 
            "citation": "Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, Wilson JM. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999 Dec 10;10(18):2973-85."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004287"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}